AstraZeneca’s Oncology Strategy Yields Victories

Tagrisso Adjuvant Data, Koselugo NF1 Approval Are Signs Of Progress

The company stopped the Phase III ADAURA study for Tagrisso early due to overwhelming efficacy and the US FDA approved selumetinib in a rare pediatric disease.

DNA strand and Cancer Cell Oncology Research Concept 3D rendering
The targeted therapies Tagrisso and selumetinib met key milestones • Source: Shutterstock

AstraZeneca PLC made progress on two fronts in its quest to build its oncology portfolio with the early unblinding of the Phase III ADAURA clinical trial of Tagrisso (osimertinib) in the adjuvant lung cancer setting and with US Food and Drug Administration approval for Koselugo (selumetinib) in its first-ever indication.

Dave Fredrickson, executive vice president of the company’s oncology business unit, told Scrip that the news announced on 10 and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip